Federica Pericle
Fondateur chez SeneXta Therapeutics SA
Profil
Dr. Federica Pericle is a Chief Operating Officer at SeneXta Therapeutics SA and a Consultant at Onelife SA. She has solid experience with large Biotech Funds, VCs, and several biotechnology companies in Europe and the USA. She is the CEO at Agilvax.
She has 25 years of research experience in the fields of cancer gene therapy, tumor biology, immunology, signal transduction, and cancer immunotherapy.
She was a Director of the Oncology Program at Valentis, in Texas.
She has also worked as a Senior Scientist at the National Cancer Institute.
She has led the research of 10 product candidates and has published over 40 scientific articles in peer-review journals.
She received her Ph.D.
in Biological Sciences from Turin University in Italy, and had a specialization in Immunology from the University of South Florida.
She also holds an MBA from Texas University.
Postes actifs de Federica Pericle
| Sociétés | Poste | Début |
|---|---|---|
Onelife SA
 Onelife SA Investment ManagersFinance Onelife SA provides investment advice. The private company is based in Lugano, Switzerland. and has subsidiaries in Luxembourg, Switzerland and Liechtenstein. The Swiss company was founded in 2006 by Enrico Braglia. Enrico Braglia has been the CEO since 2006. | Consultant / Advisor | 01/05/2007 |
SeneXta Therapeutics SA
 SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Fondateur | 18/09/2009 |
Anciens postes connus de Federica Pericle
| Sociétés | Poste | Fin |
|---|---|---|
Agilvax, Inc.
 Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Directeur Général | 25/07/2019 |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Directeur Technique/Scientifique/R&D | - |
Formation de Federica Pericle
| University of Turin | Doctorate Degree |
| University of South Florida | Graduate Degree |
| The University of Texas at Austin | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Onelife SA
Onelife SA Investment ManagersFinance Onelife SA provides investment advice. The private company is based in Lugano, Switzerland. and has subsidiaries in Luxembourg, Switzerland and Liechtenstein. The Swiss company was founded in 2006 by Enrico Braglia. Enrico Braglia has been the CEO since 2006. | Finance |
SeneXta Therapeutics SA
SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Health Technology |
